,
,
MCF)(06ème section) ,
,
, PU-PH) BLAISE Didier
, PU-PH) COSTELLO Régis
, PU-PH) CHIARONI Jacques
,
,
,
PR) (69ème section) VEY Norbert ,
,
,
,
,
, MCU-PH) LOOSVELD Marie
,
MCU-PH) POGGI Marjorie (MCF) (64ème section) ,
MCF) 65ème section) ,
,
,
,
,
, PU-PH) BARTOLI Christophe
,
,
MCF) (1ère section) MILLION Matthieu ,
,
,
,
,
,
,
,
,
,
, SCHLEINITZ Nicolas
,
,
,
, PR associé Méd. Gén. à mi--temps) BERLAND Yvon (PU--PH) Surnombre FILIPPI Simon (PR associé Méd. Gén. à mi-temps) BRUNET Philippe (PU-PH) BURTEY Stépahne
,
, MCF associé Méd. Gén. À mi-temps) JOURDE CHICHE Noémie
, MCF associé Méd. Gén à mi-temps) MOAL Valérie
, MCF associé Méd. Gén. à temps plein) GUIDA Pierre (MCF associé Méd. Gén. à mi-temps)
, MCF associé Méd. Gén. À mi-temps)
Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res, Lancet Lond Engl. 22 août, vol.161, issue.2, p.63545, 2008. ,
, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5, 2013.
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects, World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry. févr, vol.14, issue.1, p.244, 2013. ,
Cytochromes P450: génotypage et/ou phénotypage pour l'individualisation du traitement médicamenteux, Rev Mediacle Suisse. févr, 2013. ,
, Code de la santé publique-Article L3222-3. Code de la santé publique sept 24, 2018.
Clinical applications of CYP genotyping in psychiatry, J Neural Transm, vol.122, issue.1, p.528, 1996. ,
The positive and negative syndrome scale (PANSS) for schizophrenia, Schizophr Bull, vol.13, issue.2, p.26176, 1987. ,
The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients, Acta Psychiatr Scand Suppl, vol.334, p.1100, 1987. ,
, American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders
, American Psychiatric Association, 2013.
,
Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine, Arch Gen Psychiatry. sept, vol.45, issue.9, p.78996, 1988. ,
The Brief Psychiatric Rating Scale, Psychol Rep. 1 juin, vol.10, issue.3, p.799812, 1962. ,
International consensus study of antipsychotic dosing, Am J Psychiatry. juin, vol.167, issue.6, p.68693, 2010. ,
Current perspectives on chlorpromazine equivalents: Comparing apples and oranges, Indian J Psychiatry, vol.55, issue.2, p.2078, 2013. ,
,
, L'Encephale. déc, vol.33, issue.6, p.90210, 2007.
Identification and functional characterization of new potentially defective alleles of human CYP2C19, Pharmacogenetics. déc, vol.12, issue.9, p.70311, 2002. ,
Genetic variations and haplotypes of CYP2C19 in a Japanese population, Drug Metab Pharmacokinet. août, vol.20, issue.4, p.3007, 2005. ,
Identification of New Alleles and the Determination of Alleles and Genotypes Frequencies at the CYP2D6 Gene in Emiratis, PLOS ONE. 22 déc, vol.6, issue.12, p.28943, 2011. ,
Pharmacogenetics: from bench to byte-an update of guidelines, Clin Pharmacol Ther. mai, vol.89, issue.5, p.66273, 2011. ,
The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database, Clin Pharmacol Ther. mars, vol.103, issue.3, p.28943, 2007. ,
Use of probe drugs as predictors of drug metabolism in humans, J Clin Pharmacol, vol.37, issue.S1, pp.40-48, 1997. ,
La mesure de la concentration des médicaments psychotropes à l'ère de la pharmacogénétique, 2004. ,
Does the Medication Pattern Reflect the CYP2D6 Genotype in Patients With Diagnoses Within the Schizophrenic Spectrum?, J Clin Psychopharmacol. 22 déc, vol.32, p.1005, 2011. ,
CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence, Schizophr Res. sept, vol.149, issue.13, p.114, 2013. ,
,
Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics, Pharmacogenet Genomics. juill, vol.18, issue.7, p.599609, 2008. ,
The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation, J Clin Psychiatry. janv, vol.66, issue.1, p.1527, 2005. ,
The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment, Clin Pharmacol Ther, vol.72, issue.4, 2002. ,
Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses, Int J Organ Transplant Med, vol.11, issue.1, p.2733, 2011. ,
ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine, J Clin Psychopharmacol. août, vol.29, issue.4, p.31926, 2009. ,
Clozapine dosages and plasma drug concentrations, J Formos Med Assoc Taiwan Yi Zhi. août, vol.96, issue.8, p.599605, 1997. ,
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy, Clin Pharmacol Ther. août, vol.90, issue.2, p.32832, 2011. ,
PharmGKB summary: very important pharmacogene information for CYP1A2, Pharmacogenet Genomics. janv, vol.22, issue.1, 2012. ,
, polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients, J Clin Psychiatry. mai, vol.68, issue.5, p.697704, 2007.
Treatmentresistance to clozapine in association with ultrarapid CYP1A2 activity and the C->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine, J Clin Psychopharmacol. déc, vol.21, issue.6, p.6037, 2001. ,
Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene, J Clin Psychopharmacol. avr, vol.24, issue.2, p.2149, 2004. ,
Clozapine-resistant schizophrenia related to an increased metabolism and benefit of fluvoxamine ,
The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients, Ann Clin Biochem. 1 mai, vol.33, issue.5, p.2169, 2005. ,
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome, Pharmacogenomics J. févr, vol.10, issue.1, p.209, 2010. ,
Could Discontinuing Smoking Be Hazardous for Patients Administered Clozapine Medication? A Case Report, Ther Drug Monit, vol.21, p.5802, 1999. ,
, Annexe 3. Principaux cytochromes impliqués dans le métabolisme des antipsychotiques
, Amisulpride n'est métabolisé par aucun de ces cytochromes (?=voie de métabolisation principale ; ? =voie de métabolisation secondaire
, ! = métabolite actif)(30)